Effect of rosuvastatin with enoxaparin in patients with ovarian cancer undergoing ovarian cancer surgery. (A) Total EV measured in plasma at baseline (day 0) and serially (postoperative days 15, 30, and 60) in patients treated with rosuvastain (blue) and patients treated with enoxaparin alone (red) measured by flow cytometry and NTA (P = .8). (B) TF+EVs measured in plasma at baseline (day 0) and serially (postoperative days 15, 30, and 60) in patients treated with rosuvastain (blue) and patients treated with enoxaparin alone (red) measured by flow cytometry (P = .5). (C) Correlation between TF+EV levels and activity. There was no correlation between TF+EV measured by flow cytometry and TF activity (R² = 0; P = 1). (D) Serial D-dimer measurements in patients treated with rosuvastatin plus enoxaparin (blue) compared with enoxaparin alone (red; P = .9). (E) Serial CRP measurements in patients treated with rosuvastatin plus enoxaparin (blue) compared with enoxaparin alone (red; P = .9).